home / stock / xomap / xomap quote
Last: | $24.98 |
---|---|
Change Percent: | 0.01% |
Open: | $24.98 |
Close: | $24.98 |
High: | $24.98 |
Low: | $24.98 |
Volume: | 343 |
Last Trade Date Time: | 05/01/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$24.98 | $24.98 | $24.98 | $24.98 | $24.98 | 343 | 05-01-2024 |
$24.983 | $25.0286 | $24.983 | $25.0286 | $24.983 | 235 | 04-30-2024 |
$25.06 | $25.06 | $25.06 | $25.069 | $24.8851 | 1,210 | 04-29-2024 |
$24.97 | $24.85 | $24.97 | $24.9978 | $24.85 | 1,752 | 04-26-2024 |
$24.9894 | $24.88 | $24.9894 | $24.9894 | $24.88 | 550 | 04-25-2024 |
$24.8501 | $24.96 | $24.8501 | $24.96 | $24.8501 | 1,095 | 04-24-2024 |
$24.85 | $24.85 | $24.85 | $24.87 | $24.85 | 2,437 | 04-23-2024 |
$24.98 | $24.98 | $24.98 | $24.98 | $24.98 | 894 | 04-22-2024 |
$25.09 | $24.85 | $25.09 | $25.09 | $24.85 | 1,000 | 04-19-2024 |
$24.99 | $24.99 | $24.99 | $24.99 | $24.99 | 258 | 04-18-2024 |
$24.99 | $24.99 | $24.99 | $24.99 | $24.99 | 572 | 04-17-2024 |
$24.82 | $24.97 | $24.82 | $25.005 | $24.82 | 2,523 | 04-16-2024 |
$24.81 | $24.98 | $24.81 | $24.98 | $24.81 | 1,089 | 04-15-2024 |
$24.975 | $24.99 | $24.975 | $25 | $24.89 | 1,504 | 04-12-2024 |
$24.9538 | $25.01 | $24.9538 | $25.02 | $24.86 | 2,611 | 04-11-2024 |
$24.8899 | $0 | $24.8899 | $0 | $0 | 559 | 04-10-2024 |
$24.8899 | $24.85 | $24.8899 | $25 | $24.83 | 2,256 | 04-09-2024 |
$24.81 | $24.86 | $24.81 | $24.9671 | $24.81 | 3,848 | 04-08-2024 |
$24.837 | $0 | $24.837 | $0 | $0 | 45 | 04-05-2024 |
$24.837 | $24.855 | $24.837 | $24.855 | $24.837 | 662 | 04-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock Company Name:
XOMAP Stock Symbol:
NASDAQ Market:
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women’s health assets: Ovaprene ...
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE N...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggrega...